Bomedemstat

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis

Trial Timeline

Dec 1, 2022 → Dec 31, 2025

NCT ID

NCT05569538

About Bomedemstat

Bomedemstat is a phase 2 stage product being developed by Merck for Myelofibrosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05569538. Target conditions include Myelofibrosis.

What happened to similar drugs?

2 of 19 similar drugs in Myelofibrosis were approved

Approved (2) Terminated (3) Active (14)

✅ruxolitinib + panobinostatNovartisApproved

✅INC424NovartisApproved

🔄Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3

🔄Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3

❌Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3

🔄INC424NovartisPhase 3

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07049939	Phase 1	Completed	Aug 20, 2025	Feb 17, 2026	Hepatic Insufficiency
NCT06351631	Phase 3	Recruiting	May 23, 2024	Dec 4, 2034	Thrombocythemia, Essential
NCT05558696	Phase 2	Completed	Sep 7, 2023	Jul 10, 2025	Polycythemia Vera
NCT05569538	Phase 2	UNKNOWN	Dec 1, 2022	Dec 31, 2025	Myelofibrosis
NCT05223920	Phase 2	Completed	Dec 15, 2021	Aug 22, 2024	Thrombocythemia, Essential
NCT04254978	Phase 2	Completed	Sep 8, 2020	Mar 23, 2023	Essential Thrombocythemia
NCT03136185	Phase 1/2	Completed	Jul 18, 2017	Mar 8, 2022	Myelofibrosis

Competing Products

20 competing products in Myelofibrosis

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Nusivertib + Ruxolitinib + Momelotinib	Sumitomo Pharma	Phase 1/2	39
Ruxolitinib + Navitoclax	AbbVie	Phase 2	35
ABBV-744 + Navitoclax + Ruxolitinib	AbbVie	Phase 1	33
Placebo for Navitoclax + Ruxolitinib + Navitoclax	AbbVie	Phase 3	40
Mivebresib + Navitoclax + Ruxolitinib	AbbVie	Phase 1	21
Navitoclax + Venetoclax	AbbVie	Pre-clinical	26
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)	AbbVie	Phase 3	44
NS-018 + Best Available Therapy	Nippon Shinyaku	Phase 2	27
AZD1480	AstraZeneca	Phase 1	29
Peginterferon alfa-2a	Merck	Phase 2	27
Bomedemstat	Merck	Phase 1/2	32
MBG453 + NIS793 + Spartalizumab + Decitabine	Novartis	Phase 1	21
PIM447 + Ruxolitinib + LEE011	Novartis	Phase 1	29
LDE225 + INC424	Novartis	Phase 1/2	32
Imatinib mesylate	Novartis	Phase 2	35
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793	Novartis	Phase 1/2	24
Ruxolitinib + Ruxolitinib Placebo	Novartis	Phase 3	32
Ruxolitinib	Novartis	Pre-clinical	30
ruxolitinib	Novartis	Phase 2	35